Academic Sponsors / Collaborators
Interaction Checker
We have produced various materials in PDF format to aid the use of experimental agents in the treatment of COVID-19.
These resources are freely available and the Liverpool Drug Interactions Group would like to encourage the dissemination (with an appropriate acknowledgement) of this drug-drug interaction information for non-commercial use. If referencing these Prescribing Resources, it is important to include the publication date since these resources are updated as new data come to light. Please cite as: [Prescribing Resource Title], [PDF Publication Date], University of Liverpool, available from www.covid19-druginteractions.org, [accession date].
This document explains how we have evaluated the drug-drug interaction risk of the COVID-19 therapies (licensed and under clinical investigation) and gives details of their metabolism, interaction potential and cardiac effects.
This flow chart shows how a patient may be assessed when considering treatment with Paxlovid (nirmatrelvir/ritonavir; NMV/r).
This document allows users see at-a-glance the risk and management of drug-drug interactions between Paxlovid and selected drugs that may be used in the outpatient setting.
This document was developed for use in resource-limited settings where internet access is not always available and was designed to allow users see at-a-glance the risk and management of drug-drug interactions between Paxlovid and selected drugs from the WHO Essential Medicines list.
This document summarises proposed dosing guidance for Paxlovid when administered to patients with renal impairment and to patients on dialysis.
This document gives details of the duration of the CYP3A4 inhibitory effect of ritonavir and guidance as to how to manage comedications that may have been paused or dose-adjusted during treatment with Paxlovid (nirmatrelvir/ritonavir).
Data supporting the crushing nirmatrelvir and ritonavir tablets for administration in cases of swallowing difficulties or via feeding tubes are given in this document.
This document gives details of how the interaction profile of Paxlovid differs when used for a 5 day treatment duration or for an extended treatment duration.
Details of the nature of drug interactions with key COVID-19 therapies and many comedication classes are given in this PDF.
A summary of interactions with COVID-19 antiviral therapies (licensed or under clinical investigation) and over 1100 comedications are given in this PDF.
A summary of interactions with COVID-19 host-directed therapies (licensed or under clinical investigation) and over 1100 comedications are given in this PDF.
Advice for administering COVID-19 therapies (licensed or under clinical investigation) to patients who cannot swallow is given in this PDF.
Details of dose modifications for COVID-19 therapies (licensed or under clinical investigation) which may be required for patients with renal impairment are given in this PDF.
UPDATED - revised recommendations for remdesivir.
Details of dose modifications for COVID-19 therapies (licensed or under clinical investigation) which may be required for patients with hepatic impairment are given in this PDF.
